Recent progress concerning CpG DNA and its use as a vaccine adjuvant.
Recent progress concerning CpG DNA and its use as a vaccine adjuvant.
复制标题
DOI：
10.1586/14760584.2014.863715
复制
发表时间：
2014-03
影响因子：
6.2
通讯作者：
Klinman DM
中科院分区：
文献类型：
--
作者：
Shirota H;Klinman DM
CpG寡核苷酸（ODN）是设计用于特异性激动Toll样受体9的免疫调节性合成寡核苷酸。本文综述了CpG ODN作用机制的最新进展，并概述了利用CpG ODN改进癌症、过敏和传染病疫苗的人体临床试验结果。
CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.